GlyHealth-COVID is being developed to identify immunofrail individuals likely to suffer serious inflammatory episodes if they were to be infected with SARS-Cov-2 virus.
The first phase of this program was being funded as part of the UK Research and Innovation (UKRI) initiative for research addressing COVID-19 with blood samples from patients across the UK, Europe and the US. See more details here. Our preliminary results indicate that there are blood glycomics patterns of individuals that seem to correlate with health outcomes after SARS-Cov-2 infection.
We continue our study with Ludger to establish whether health outcomes from covid-19 infection are related to another established indicator of an individual’s general immune-health, that is, does one aspect of their immune response to disease, lifestyle and aging indicate higher than desirable levels of chronic inflammation. It is hypothesised that individuals with higher levels of chronic inflammation may have poorer health outcomes when infected with covid-19.
We are currently working with clinical partners to establish a basic understanding of the disease’s relationship and inflammation, and this has been on-going for about 12 months. We want to do further testing to understand correlations between glycomic patterns and other variable such as age, sex, ethnicity, known pre-existing chronic diseases and pre-existing sub-clinical chronic conditions.